Dow up 0.08% Nasdaq down 0.30%
{"s" : "^dji,^ixic","k" : "p20","o" : "","j" : ""}
 Dow up 0.08% Nasdaq down 0.30%
{"s" : "^dji,^ixic","k" : "p20","o" : "","j" : ""}

Quote Results

Add Quotes

SymbolTime & PriceChg & % ChgDay's Low & HighVolumeAvg VolMkt CapChartMore Info
Sep 19 60.49 +0.18 +0.30% 60.49 60.89 14,484,992 8,355,590 174.49B Sparkline Chart Chart, News, Stats, Options, Board
No such ticker symbol: REAL-TIMETry Symbol Lookup
{"s" : "mrk","k" : "t53,l84,c63,p43,g53,h53,v53,j10,c63,l84,p43,a00,a50,b00,b60,g00,h00,t53,v53","o" : "","j" : "c63,l84,p43,t53,v53"}

Quotes delayed, except where indicated otherwise.

Recent News

day and time symbols news headline and source
Friday September 19, 2014
Is Merck KGaA on Track with its "Fit for 2018" Program? Zacks01:50pm EDT
Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal PR Newswire11:00am EDT
Thursday September 18, 2014
Merck KGaA Teams Up with Sutro for ADCs Targeting Cancer Zacks06:00pm EDT
Bayer Deal for Zoetis in Sight After Unit Sale: Real M&A at Bloomberg04:56pm EDT
Merck Enters into Licensing Agreement with Sun Pharma Zacks03:55pm EDT
Credit Suisse Gold Standard Yield Stocks May Be the Safest to Own Now 24/7 Wall St.08:15am EDT
Bayer to float plastics business and focus on life sciences at Financial Times07:36am EDT
Merck KGaA seeks partner for immuno-oncology drug by year-end Reuters06:12am EDT
Wednesday September 17, 2014
Sun Pharma licenses Merck psoriasis drug for $80M AP11:10am EDT
Merck licenses experimental psoriasis drug to India's Sun Pharma Reuters10:12am EDT
Dow Jones (DJIA) Today: E I Du Pont De Nemours & Company (DD) Leads The Day Higher, Merck (MRK) Lags at TheStreet10:00am EDT
Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes Business Wire09:31am EDT
8:32 am Merck and Sun Pharma enter into licensing agreement for Tildrakizumab; Sun will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80 mln Briefing.com08:32am EDT
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab Business Wire08:30am EDT
Tuesday September 16, 2014
Merck KGaA-Lupin Ink Deal, Focus on Emerging Markets Zacks03:14pm EDT
Dow Jones (DJIA) Today: Merck (MRK) Higher at TheStreet02:00pm EDT
Ebola under the microscope CNBC06:35am EDT
[video] Ebola under the microscope at CNBC06:35am EDT
Monday September 15, 2014
Merck osteoporosis drug passes trial, but side effects hover Reuters04:51pm EDT
Merck KGaA Stops All Tecemotide Studies for Lung Cancer Zacks02:42pm EDT
Merck's Osteoporosis Drug Meets Primary Fracture Endpoints In Phase 3 Trial at Forbes02:36pm EDT
Merck says osteoporosis drug achieves goal in large trial Reuters01:56pm EDT